Physician profile
Eric S Kemp
NPI 1174681589
$2,444.20
in general payments reported to CMS, 2019-2025
19 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $334 · 2021: $440 · 2022: $227 · 2023: $258 · 2024: $359 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $370.80 | 2019-2022 | |
| Tris Pharma INC | $305.18 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $202.48 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $193.94 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $170.69 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $154.85 | 2019-2025 | Lybalvi, Aristada |
| Allergan, INC. | $143.00 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $124.86 | 2019-2022 | |
| Corium, LLC | $121.62 | 2024-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $116.33 | 2020-2024 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $101.39 | 2019-2022 | |
| Indivior INC. | $94.20 | 2020-2024 | Perseris |
| Collegium Pharmaceutical, INC. | $76.42 | 2025 | Jornay Pm |
| Eisai INC. | $73.00 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.67 | 2020-2024 | Caplyta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $51.93 | 2019-2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $35.17 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $34.05 | 2025 | Xelstrym, Secuado |
| Merck Sharp & Dohme LLC | $18.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.